Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Zi Portres Group Kompani | New Parm Group | Ji-I-Es-Ei Parmatsevtik… | Parmahabi | Asemod |
|---|---|---|---|---|---|
| Total Revenue | 14,740 | 6,688 | 5,854 | 5,471 | 4,491 |
| Total COGS | -6,288 | -3,002 | -3,909 | -5,046 | -3,082 |
| Gross Profit | 8,452 | 3,686 | 1,945 | 425 | 1,410 |
| Gross Margin | 57.3% | 55.1% | 33.2% | 7.8% | 31.4% |
| Total Operating Expenses | -220 | -2,172 | -46 | 605 | -350 |
| EBITDA | 8,232 | 1,515 | 1,899 | 1,030 | 1,060 |
| EBITDA Margin | 55.8% | 22.6% | 32.4% | 18.8% | 23.6% |
| Total D&A | 0 | -41 | 0 | -1 | -5 |
| EBIT / Operating Income | 8,232 | 1,473 | 1,899 | 1,029 | 1,055 |
| Profit Before Tax | 8,232 | 1,416 | 2,028 | 1,727 | 1,056 |
| Total Income Tax | 0 | -246 | 0 | 0 | 0 |
| Net Profit / (Loss) | 8,232 | 1,170 | 2,028 | 1,085 | 1,056 |
| Net Margin | 55.8% | 17.5% | 34.6% | 19.8% | 23.5% |
| Total Interest Expense | — | -57 | — | -3 | -38 |
| Total Other Income | — | — | 129 | 700 | 40 |
| Company | Sector | EBITDA margin · FY 2021 | Percentile | Sector n |
|---|---|---|---|---|
| Zi Portres Group Kompani | Pharma | 55.8% | 99th pct | 116 |
| Ji-I-Es-Ei Parmatsevtik… | Pharma | 32.4% | 82nd pct | 116 |
| Asemod | Pharma | 23.6% | 68th pct | 116 |
| New Parm Group | Pharma | 22.6% | 65th pct | 116 |
| Parmahabi | Pharma | 18.8% | 53rd pct | 116 |
Percentile is within each company's own sector across the whole FY2021 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.